Drug Profile

Research programme: rhomboid protease inhibitors - Academy of Sciences Czech Republic/Enamine/MRC

Latest Information Update: 16 Jul 2016

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Academy of Sciences of the Czech Republic; Enamine; Medical Research Council
Class Small molecules
Mechanism of Action Rhomboid protease inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

No development reported Cancer; Cardiovascular disorders; Immunological disorders; Infections; Parasitic infections

16 Jul 2016 No recent reports of development identified for research development in Cancer in Czech Republic
16 Jul 2016 No recent reports of development identified for research development in Cancer in Ukraine
16 Jul 2016 No recent reports of development identified for research development in Cancer in United Kingdom

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com